Details of the Drug

General Information of Drug (ID: DM4L59B)

• Drug Name: Teprotumumab
• Synonyms: RV001

Indication

Disease Entry	ICD 11	Status	REF
Graves disease	5A02.0	Approved	[1]
Diabetic macular edema	9B71.02	Phase 1	[2]

• ADMET Property:
  Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 138000 +/- 34 mgh/L [3]
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 632 +/- 139 mg/L [3]
  Clearance: The clearance of drug is 0.27 L/day [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 20 +/- 5 days [3]
  Vd: The volume of distribution (Vd) of drug is 3.26 +/- 0.87 L [3]
• Cross-matching ID:
  DrugBank ID: DB06343
  TTD ID: D0EN0W

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Insulin-like growth factor I receptor (IGF1R)	TTHRID2	IGF1R_HUMAN	Antagonist	[1]

Molecular Expression Atlas of This Drug

• The Studied Disease: Graves disease
• ICD Disease Classification: 5A02.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Insulin-like growth factor I receptor (IGF1R)	DTT	IGF1R	1.64E-01	0.25	0.64

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] FDA Approved Drug Products: Tepezza (teprotumumab-trbw) for intravenous injection
• [4] IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch. 2003 Aug;443(2):139-45.
• [5] 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
• [6] Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family... Bioorg Med Chem Lett. 2010 Apr 15;20(8):2452-5.
• [7] Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3. Drugs R D. 2005;6(2):120-7.
• [8] MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014 Feb;13(2):410-25.
• [9] BiPar Sciences Co-founder Reunites Management Team At TriAct Therapeutics to Advance Clinical Stage Cancer Programs. TriAct Therapeutics. Sept. 10, 2009.
• [10] Clinical pipeline report, company report or official report of Amgen (2009).
• [11] Clinical Phase I study with an Insulin-like Growth Factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma. Acta Oncol. 2011 Apr;50(3):441-7.
• [12] Clinical pipeline report, company report or official report of Roche (2009).